Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin‐based chemotherapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|16|3012-3019

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.16, 2013-08, pp. : 3012-3019

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3020-3026

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biweekly Carboplatin/Gemcitabine in Patients with Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: Report of Efficacy, Quality of Life and Geriatric Assessment

By  

Oncology, Vol. 73, Iss. 5-6, 2008-05 ,pp. : 290-297

Karger

Access to resources Recommend Favorite

Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin?

By  

Oncology Research and Treatment, Vol. 26, Iss. 5, 2003-11 ,pp. : 462-467

Karger

Access to resources Recommend Favorite

Outcome post‐neoadjuvant chemotherapy in elderly

By  

EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol. 24, Iss. 2, 2015-03 ,pp. : 155-162

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adjuvant cisplatin‐based combined chemotherapy for lymph node (LN)‐positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of

By  

BJU INTERNATIONAL, Vol. 115, Iss. 5, 2015-05 ,pp. : 722-727

John Wiley & Sons Inc

Access to resources Recommend Favorite